New Approaches to Dementia Heterogeneity
New Approaches to Dementia Heterogeneity
批准号:
10647902
负责人:
Gil Dan Rabinovici
金额:
$346.14万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-05-01 至 2024-03-31
关键词:
AccelerationAgingAlzheimer&aposs DiseaseAmericanAwardBasic ScienceBiologicalBiological MarkersBiologyBiometryCaregiver supportCaringChineseClinicalClinical TrialsCognition DisordersCollaborationsCollectionCommunitiesCreutzfeldt-Jakob SyndromeDataDementiaDiagnosisDiagnosticDiseaseEarly Onset Alzheimer DiseaseEducationEndowmentEvaluationFilmFoundationsFrontotemporal DementiaFundingGenerationsGeneticGenomicsGrantHeterogeneityImageIndustry CollaborationInternationalK-Series Research Career ProgramsKnowledgeLatinoLeadLeadershipMedicalMemoryMinorityModelingMolecularNeurodegenerative DisordersNeurologicNeurologistNeurosciencesNursesOnline SystemsPathologicPathologyPerformancePhysiologicalPoliciesPopulation HeterogeneityProcessProgressive Supranuclear PalsyProteomicsPublic HealthResearchResearch PersonnelResourcesSamplingScienceScientistSiteSpecialistSpecialized CenterTabletsTalentsTauopathiesTrainingUnited States National Institutes of HealthWorkbrain healthcareercatalystclinical centerclinical diagnosticsclinical phenotypecohortcommunity centercorticobasal syndromedata managementdata sharingdrug developmenteducation researchethnic diversitygender diversityhealth care deliveryhealth economicshealth equityhealthy agingimprovedinnovationlecturesnormal agingnovelnovel strategiesoutreachprogramsrecruitstatisticssymposiumtau Proteinstherapy developmenttranscriptomicstranslational scientist
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
The UCSF Alzheimer’s Disease Research Center (ADRC) is a major catalyst for a broad spectrum of
dementia-related research conducted at UCSF and has served as a cornerstone for national and international
multi-site diagnostic and treatment studies. In three previous cycles of funding under the P50 mechanism, we
have organized a critical mass of dementia research and share our resources widely. We excel in clinical
phenotyping, imaging, biospecimen collection, and pathologic evaluation of large and unique cohorts of early-
onset AD (EOAD), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), corticobasal
syndrome (CBS), Creutzfeldt-Jakob disease (CJD), and healthy controls. The ADRC supports and effectively
leverages additional NIH and foundation funding, philanthropy, and industry collaborations to accomplish its
aims. At the UCSF Memory and Aging Center alone, ADRC clinical cohorts, data, and biosamples are currently
utilized by 26 R grants, 6 K awards, 4 U grants, and 38 non-NIH grants. Projects and pilot awards have helped
launch young investigator careers and major research programs. ADRC data and biosamples are utilized
extensively by other ADRCs and an extensive network of collaborators.
In this new P30 application, we accelerate efforts to define subtypes of healthy aging, MCI, AD, FTD, PSP,
CBS, and CJD that predict specific molecular and physiological causes for dementia, improve early recognition
and tracking of transitions from normal aging to dementia, and stimulate drug development and clinical trials.
The ADRC will consist of seven cores: Administrative, Clinical, Data Management and Statistics, Pathology,
Outreach Recruitment and Engagement, Imaging, and Biomarker and a Research Education Component. These
cores will work collectively to pursue the following overarching specific aims: Aim 1: Explore the heterogeneous
features of healthy aging, MCI, AD, FTD-spectrum disorders, and CJD to better understand their clinical, genetic,
and molecular underpinnings. Aim 2: Leverage the valuable cohorts in the ADRC and the talented neuroscience
communities at UCSF and beyond to “enhance the performance of innovative research” around diagnosis and
treatment of dementia. Aim 3: Increase understanding of the unique cultural and biological features of aging
Chinese and Latino Americans, while educating these communities with outreach lectures and web-based
presentations. Aim 4: Develop innovative approaches to data management and biostatistics to support easy
access and analysis of ADRC-related data while offering statistical support to our investigators. Aim 5: Train
new leaders in dementia research with innovative education approaches and educate medical and lay
communities about the heterogeneity of dementia with conferences, web-based presentations, and films.
Aim 6: Create a new Biomarker Core to enhance the genomic, proteomic, and transcriptomic data captured from
our extensive biospecimen collection. Aim 7: Transition to a more gender and ethnically diverse ADRC
leadership by 2024.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia.
慢性创伤性脑病:与阿尔茨海默病和额颞叶痴呆的比较。
DOI:
10.1055/s-0040-1715134
发表时间:
2020
期刊:
Seminars in neurology
影响因子:
2.7
作者:
[Lesman-Segev,OritH, Edwards,Lauren, Rabinovici,GilD]
通讯作者:
Rabinovici,GilD
DOI:
10.3389/fneur.2023.1247480
发表时间:
2023
期刊:
Frontiers in neurology
影响因子:
3.4
作者:
[]
通讯作者:
Corticobasal syndrome with visual hallucinations and probable REM-sleep behavior disorder: an autopsied case report of a patient with CBD and LBD pathology.
皮质基底节综合征伴视幻觉和可能的快速眼动睡眠行为障碍:一名患有 CBD 和 LBD 病理学的患者的尸检病例报告。
DOI:
10.1080/13554794.2019.1604973
发表时间:
2019
期刊:
Neurocase
影响因子:
0.8
作者:
[Naasan,George, Shany-Ur,Tal, Sidhu,Manu, Barton,Cynthia, Ketelle,Robin, Shdo,SuzanneM, Kramer,JoelH, Miller,BruceL, Seeley,WilliamW]
通讯作者:
Seeley,WilliamW
Rapid Isolation of Functional Synaptic Vesicles from Tissues Through Cryogrinding, Ultracentrifugation, and Size Exclusion Chromatography.
通过冷冻研磨、超速离心和尺寸排阻色谱从组织中快速分离功能性突触小泡。
DOI:
10.1007/978-1-0716-1916-2_10
发表时间:
2022
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Li,Huinan]
通讯作者:
Li,Huinan
DOI:
10.15252/emmm.202114408
发表时间:
2022-01-11
期刊:
EMBO molecular medicine
影响因子:
11.1
作者:
[Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O]
通讯作者:
Hansson O
New Approaches to Dementia Heterogeneity
-
批准号:10431778
-
项目类别:
-
资助金额:$346.14万
-
财政年份:2019
-
负责人:Gil Dan Rabinovici
-
依托单位:
Core A: Administrative Core
-
批准号:10431779
-
项目类别:
-
资助金额:$96.89万
-
财政年份:2019
-
负责人:Gil Dan Rabinovici
-
依托单位:
Core A: Administrative Core
-
批准号:10647903
-
项目类别:
-
资助金额:$83.72万
-
财政年份:2019
-
负责人:Gil Dan Rabinovici
-
依托单位:
Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration
-
批准号:9212684
-
项目类别:
-
资助金额:$61.7万
-
财政年份:2014
-
负责人:Gil Dan Rabinovici
-
依托单位:
Early Age-of-Onset AD: Clinical Heterogeneity and Network Degeneration
-
批准号:8696557
-
项目类别:
-
资助金额:$66.15万
-
财政年份:2014
-
负责人:Gil Dan Rabinovici
-
依托单位:
Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations
-
批准号:8113958
-
项目类别:
-
资助金额:$15.94万
-
财政年份:2008
-
负责人:Gil Dan Rabinovici
-
依托单位:
Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations
-
批准号:7690782
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2008
-
负责人:Gil Dan Rabinovici
-
依托单位:
Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations
-
批准号:7898716
-
项目类别:
-
资助金额:$15.93万
-
财政年份:2008
-
负责人:Gil Dan Rabinovici
-
依托单位:
Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations
-
批准号:8287586
-
项目类别:
-
资助金额:$15.94万
-
财政年份:2008
-
负责人:Gil Dan Rabinovici
-
依托单位:
Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations
-
批准号:7588450
-
项目类别:
-
资助金额:$15.78万
-
财政年份:2008
-
负责人:Gil Dan Rabinovici
-
依托单位:
Project 1: Early-Onset Alzheimers Disease: Imaging and Genetic Phenotypes
-
批准号:9248863
-
项目类别:
-
资助金额:$15.13万
-
财政年份:2004
-
负责人:Gil Dan Rabinovici
-
依托单位:
Project 1: Early-Onset Alzheimers Disease: Imaging and Genetic Phenotypes
-
批准号:9054052
-
项目类别:
-
资助金额:$14.85万
-
财政年份:2004
-
负责人:Gil Dan Rabinovici
-
依托单位:
Project 1: Early-Onset Alzheimers Disease: Imaging and Genetic Phenotypes
-
批准号:8677149
-
项目类别:
-
资助金额:$14.71万
-
财政年份:2004
-
负责人:Gil Dan Rabinovici
-
依托单位:
Project 1: Early-Onset Alzheimers Disease: Imaging and Genetic Phenotypes
-
批准号:8829106
-
项目类别:
-
资助金额:$14.34万
-
财政年份:2004
-
负责人:Gil Dan Rabinovici
-
依托单位:
海外基金